{"editorial":{"content_id":"28bc8c05-678a-4b49-81f1-59d48f37c8ee","slug":"anvisa-hipolabor-medkaya-20261113-64417c","content_type":"news","title":"Anvisa召回Hipolabor麻醉剂批次并禁止Medkaya大麻产品广告","summary":"巴西国家卫生监督局11月13日发布决议，召回Hipolabor公司生产的盐酸布比卡因+葡萄糖注射液批次AR-001/25，并禁止Medkaya公司大麻产品的广告。","body":"巴西国家卫生监督局（Anvisa）于11月13日（周五）发布决议，要求召回由Hipolabor Farmacêutica公司（CNPJ: 19.570.720/0001-10）生产的麻醉剂「盐酸布比卡因+葡萄糖（5+80）MG/ML 注射液 IV CX 100 AMP vVD TRANS X 4 ml」批次AR-001/25，禁止该批次产品的销售、分销和使用；同一决议还禁止了Medkaya Produtos e Serviços Farmacêuticos公司（CNPJ: 28.604.566/0001-41）生产的大麻产品广告。\n\n据决议，召回原因是圣保罗州Adolfo Lutz研究所（Lacen）的检验报告显示，该药品在样品描述和外观检测中结果不合格，原因是药品中存在异物颗粒。\n\n同一决议禁止广告的Medkaya公司产品此前在网站 https://medkayafarma.com.br/ 上销售。\n\n相关决议编号为4.427/2026，已在《联邦官方公报》（DOU）上公布。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["合规","政策","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-11-13T17:01:36.776Z","display_date":"2026-11-13","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-determina-recolhimento-de-anestesico-e-proibe-propaganda-de-produtos-de-cannabis","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-hipolabor-medkaya-20261113-64417c","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-hipolabor-medkaya-20261113-64417c","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-hipolabor-medkaya-20261113-64417c?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-hipolabor-medkaya-20261113-64417c?view=json","last_updated":"2026-11-13T17:02:02.104Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}